Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
109
-
Total 13F shares, excl. options
-
28.9M
-
Shares change
-
+2.68M
-
Total reported value, excl. options
-
$469M
-
Value change
-
+$47.1M
-
Put/Call ratio
-
0.55
-
Number of buys
-
44
-
Number of sells
-
-57
-
Price
-
$16.25
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q1 2017
142 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q1 2017.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.9M shares
of 108M outstanding shares and own 26.78% of the company stock.
Largest 10 shareholders include FMR LLC (6.51M shares), BlackRock Inc. (3.57M shares), VANGUARD GROUP INC (2.74M shares), BB BIOTECH AG (1.93M shares), WASATCH ADVISORS INC (1.01M shares), Hillhouse Capital Management, Ltd. (1M shares), STATE STREET CORP (910K shares), Clough Capital Partners L P (899K shares), CITADEL ADVISORS LLC (801K shares), and Rhenman & Partners Asset Management AB (716K shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.